Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 8:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–9 of 9 matching trials from the live ClinicalTrials.gov search.

Conditions: Diabetes Mellitus, Type 1, Type 1 Diabetes, Diabetes, Autoimmune, Diabetes type1, Autoimmune Diabetes, Diabetes Mellitus, Brittle, Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus, Insulin-Dependent, 1, Diabetes Mellitus, Juvenile-Onset, Diabetes Mellitus, Ketosis-Prone, Diabetes Mellitus, Sudden-Onset, Insulin-Dependent Diabetes Mellitus 1, Juvenile-Onset Diabetes, Type 1 Diabetes Mellitus
Interventions: Bionic Pancreas, Usual Care; Device · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 85 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Aurora, Colorado • Boston, Massachusetts

Conditions: Type 1 Diabetes Mellitus
Interventions: Islet transplantation with Tegoprubart (AT-1501) immunosupression-based therapy; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetes Mellitus, Type 1
Interventions: Allogenic islet cells (human, U. Chicago), Intraportal infusion of islet cells; Biological · Procedure
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2030
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Type 1 Diabetes Mellitus, Hypoglycemia, Labile Diabetes, End-stage Renal Disease
Interventions: Allogeneic islets of Langerhans; Biological
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 70 Years
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Type 1 Diabetes Mellitus
Interventions: Allogenic Human Islet Cells, Immunosuppressive Agents, Gastrin 17; Biological · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 68 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 1
States / cities: Duarte, California

Conditions: Diabetes Mellitus
Interventions: Pulsatile Intravenous Insulin Therapy (Humulin, Humulog, Novolog ); Procedure
Lead sponsor: Florida Atlantic University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Brittle Type 1 Diabetes Mellitus
Interventions: AT-1501 IV Infusion, Isolated cadaveric islet cells; Biological
Lead sponsor: Eledon Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetes Mellitus, With Complications
Interventions: Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog); Procedure
Lead sponsor: Florida Atlantic University; Other
Eligibility: 21 Years to 85 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Boca Raton, Florida

Search by objective public record fields.